Citations for: FDA Ortho Evra Information

Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
97% bound. Mainly to serum albumin. No binding to SHBG, but induces SHBG synthesis.
Ethinyl Estradiol (API)
Toxicology Data Field
Adverse effects attributed to estrogenic and metabolic effects. Water and sodium retention, which may lead to weight gain, edema, and tender breast enlargement. Changes in libido and withdrawal vaginal bleeding. Liver function impairment, jaundice, and gallstones may occur. Headache, depression, dizziness, glucose intolerance, and a sensitivity to contact lenses have been reported. Nausea, vomiting and break through vaginal bleeding are not uncommon. Dermatological effects include chloasma, melasma, rashes, and urticaria. Erytheme multiforme and erytheme nodosum occur. Hypertension and thromoboembolic disease are reported.
Ortho Evra adverse effects: breast symptoms, headache, application site reaction, nausea, upper respiratory infection, menstrual cramps, abdominal pain.
Ethinyl Estradiol (API)
Metabolites
N/A
Pharmacology Data Field
>97% bound, primarily to albumin. No binding to SHBG, except as metabolite norgestrel.
Norelgestromin (API)